1. American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry. 2001;158(10 suppl):1-52.
2. Barrash J, Kroll J, Carey K, et al. Discriminating borderline disorder from other personality disorders. Cluster analysis of the diagnostic interview for borderlines. Arch Gen Psychiatry. 1983;40(12):1297-1302.
3. Kety SS, Rosenthal D, Wender PH, et al. Mental illness in the biological and adoptive families of adopted individuals who have become schizophrenic: a preliminary report based on psychiatric interviews. Proc Annu Meet Am Psychopathol Assoc. 1975;(63):147-165.
4. Diagnostic and statistical manual of mental disorders, 3rd ed. Washington DC: American Psychiatric Association; 1980.
5. Serban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry. 1984;141(11):1455-1458.
6. Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry. 1986;43(7):680-686.
7. Soloff PH, George A, Nathan RS, et al. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry. 1986;43(7):691-697.
8. Soloff PH, George A, Nathan RS, et al. Paradoxical effects of amitriptyline on borderline patients. Am J Psychiatry. 1986;143(12):1603-1635.
9. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45(2):111-119.
10. Markovitz PJ, Calabrese JR, Schulz SC, et al. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry. 1991;148(8):1064-1067.
11. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997;54(12):1081-1088.
12. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15(1):23-29.
13. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28(6):1186-1197.
14. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63(5):442-446.
15. Schulz SC, Camlin KL, Berry SA, et al. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999;46(10):1429-1435.
16. Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65(1):104-109.
17. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2001;62(11):849-854.
18. Schulz SC, Zanarini MC, Bateman A, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008;193(6):485-492.
19. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163(5):833-838.
20. Adityanjee, Romine A, Brown E, et al. Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry. 2008;20(4):219-226.
21. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry. 2005;66(10):1298-1303.
22. Rocca P, Marchiaro L, Cocuzza E, et al. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry. 2002;63(3):241-244.
23. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind placebo-controlled pilot study. Am J Psychiatry. 2003;160(1):167-169.
24. Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010;71(1):14-25.
25. Moen Moore R, Miller M, Lee S, et al. Extended release divalproex for borderline personality disorder. Poster presented at: U. S. Psychiatric and Mental Health Congress; October 13-16, 2007; Orlando, FL.
26. Nose M, Cipriani A, Biancosino B, et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2006;21(6):345-353.
27. Lieb K, Völlm B, Rücker G, et al. Pharmacotherapy for borderline personality disorder: Cochrane Systematic Review of Randomised Trials. Br J Psychiatry. 2010;196(1):4-12.
28. Stoffers J, Völlm BA, Rücker G, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;(6):CD005653.-
29. National Collaborating Centre for Mental Health. Borderline personality disorder: the NICE guideline on treatment and management. National clinical practice guideline no. 78. London United Kingdom: RCPsych Publications; 2009.
30. Linehan MM, McDavid JD, Brown MZ, et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69(6):999-1005.
31. Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162(6):1221-1224.
32. Simpson EB, Yen S, Costello E, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65(3):379-385.
33. Zanarini MC, Vujanovic AA, Parachini EA, et al. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord. 2003;17(3):233-242.
34. Pfohl B, Blum N, St John D, et al. Reliability and validity of the Borderline Evaluation of Severity Over Time (BEST): a self-rated scale to measure severity and change in persons with borderline personality disorder. J Pers Disord. 2009;23(3):281-293.
35. Silk KR. Collaborative treatment for patients with personality disorders. In: Riba MB Balon R, eds. Psychopharmacology and psychotherapy: a collaborative approach. Washington, DC: American Psychiatric Press; 1999:221–277.
36. Zanarini MC. Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep. 2004;6(1):66-70.
